GlaxoSmithKline expects its respiratory drug Advair to report a decline in sales in 2017 in the event that generic versions of the drug are approved by the FDA. During his last investor call — new CEO ...
Even with looming generic competition expected to take a big bite out of sales of its blockbuster Advair, respiratory drugs remain key to GlaxoSmithKline, and it continues to plow money into their ...
MILWAUKEE — The 2001 product launch of the asthma drug Advair was a lavish, Las Vegas affair. Using images of a slot machine, top GlaxoSmithKline executives took the stage in front of thousands of ...
LONDON (Reuters) - Generic drugmakers, hoping for rich pickings from the launch of copies of GlaxoSmithKline's best-selling Advair inhaler in the United States next year, say they can win business ...
Even after going off patent in some markets, GlaxoSmithKline's Advair looked like the gift that would keep on giving. Its sophisticated inhaler device made it difficult to copy, protecting sales of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results